NCT06375031View on ClinicalTrials.gov

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

July 15, 2024

Conditions
Diabetes
Interventions
DRUG

HR011408 injection; HR011408 injection Placebo

"Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum"

DRUG

NovoRapid®; HR011408 injection Placebo

"Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum"

DRUG

HR011408 injection Placebo; HR011408 injection

"Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum"

Trial Locations (1)

230601

RECRUITING

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY